Eric Crombez
CIK 1653052 · EVP and Chief Medical Officer · last filed 2026-05-15
Eric Crombez is an EVP and Chief Medical Officer who has filed 21 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing, for ABEO, was dated May 15, 2026. Across all open-market trades the lifetime net is −$922.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.0M across reported positions. 11 SEC filings were submitted jointly with Ultragenyx Pharmaceutical Inc. 2 Form 144 notices of planned sales are also on file; the latest, for ABEO on May 15, 2026, lists the filer as a director.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RARE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
60 LEVERONI COURT
NOVATO, CA 94949
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ABEO | Director | 37,313 | $2.48 | $92.7K | -$260.2K | 6 | 2026-05-15 |
| RARE | EVP and Chief Medical Officer | 111,189 | $17.16 | $1.91M | -$662.6K | 10 | 2026-05-06 |
| Dimension Therapeutics, Inc. (DMTX) Delisted | Chief Medical Officer | — | — | — | $0 | 3 | 2017-11-07 |
Recent Filings
21 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-15 | ABEO | Notice (144) Director · Planned May 15, 2026 · 10b5-1 plan Sold: Form 4 filed May 15, 2026 |
−26,143 | -$144.6K | EDGAR |
| 2026-05-15 | ABEO | Sell (S)10b5-1 Plan adopted Feb 4, 2026 |
−26,143 | -$144.6K | EDGAR |
| 2026-05-06 | RARE | Sell (S) | −344 | -$8.6K | EDGAR |
| 2026-04-20 | RARE | Grant (A) | +34,674 | $0 | EDGAR |
| 2026-03-03 | RARE | Mixed | +4,614 | -$160.3K | EDGAR |
| 2026-02-02 | ABEO | Notice (144) Director · Planned Feb 2, 2026 Sold: Form 4 filed Feb 2, 2026 |
−16,284 | -$82.9K | EDGAR |
| 2026-02-02 | ABEO | Sell (S) | −16,284 | -$82.9K | EDGAR |
| 2026-01-27 | ABEO | Grant (A) | +37,313 | $0 | EDGAR |
| 2025-08-15 | ABEO | Sell (S) | −4,718 | -$32.7K | EDGAR |
| 2025-05-05 | RARE | Sell (S) | −762 | -$28.9K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).